Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) rece...
Ausführliche Beschreibung
Autor*in: |
Ane Ogbe [verfasserIn] Matthew Pace [verfasserIn] Mustapha Bittaye [verfasserIn] Timothy Tipoe [verfasserIn] Sandra Adele [verfasserIn] Jasmini Alagaratnam [verfasserIn] Parvinder K. Aley [verfasserIn] M. Azim Ansari [verfasserIn] Anna Bara [verfasserIn] Samantha Broadhead [verfasserIn] Anthony Brown [verfasserIn] Helen Brown [verfasserIn] Federica Cappuccini [verfasserIn] Paola Cinardo [verfasserIn] Wanwisa Dejnirattisai [verfasserIn] Katie J. Ewer [verfasserIn] Henry Fok [verfasserIn] Pedro M. Folegatti [verfasserIn] Jamie Fowler [verfasserIn] Leila Godfrey [verfasserIn] Anna L. Goodman [verfasserIn] Bethany Jackson [verfasserIn] Daniel Jenkin [verfasserIn] Mathew Jones [verfasserIn] Stephanie Longet [verfasserIn] Rebecca A. Makinson [verfasserIn] Natalie G. Marchevsky [verfasserIn] Moncy Mathew [verfasserIn] Andrea Mazzella [verfasserIn] Yama F. Mujadidi [verfasserIn] Lucia Parolini [verfasserIn] Claire Petersen [verfasserIn] Emma Plested [verfasserIn] Katrina M. Pollock [verfasserIn] Thurkka Rajeswaran [verfasserIn] Maheshi N. Ramasamy [verfasserIn] Sarah Rhead [verfasserIn] Hannah Robinson [verfasserIn] Nicola Robinson [verfasserIn] Helen Sanders [verfasserIn] Sonia Serrano [verfasserIn] Tom Tipton [verfasserIn] Anele Waters [verfasserIn] Panagiota Zacharopoulou [verfasserIn] Eleanor Barnes [verfasserIn] Susanna Dunachie [verfasserIn] Philip Goulder [verfasserIn] Paul Klenerman [verfasserIn] Gavin R. Screaton [verfasserIn] Alan Winston [verfasserIn] Adrian V.S. Hill [verfasserIn] Sarah C. Gilbert [verfasserIn] Miles Carroll [verfasserIn] Andrew J. Pollard [verfasserIn] Sarah Fidler [verfasserIn] Julie Fox [verfasserIn] Teresa Lambe [verfasserIn] John Frater [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2022 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: JCI Insight - American Society for Clinical investigation, 2020, 7(2022), 7 |
---|---|
Übergeordnetes Werk: |
volume:7 ; year:2022 ; number:7 |
Links: |
---|
Katalog-ID: |
DOAJ043577830 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ043577830 | ||
003 | DE-627 | ||
005 | 20230308072853.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230227s2022 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)DOAJ043577830 | ||
035 | |a (DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a Ane Ogbe |e verfasserin |4 aut | |
245 | 1 | 0 | |a Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. | ||
650 | 4 | |a AIDS/HIV | |
650 | 4 | |a COVID-19 | |
653 | 0 | |a Medicine | |
653 | 0 | |a R | |
700 | 0 | |a Matthew Pace |e verfasserin |4 aut | |
700 | 0 | |a Mustapha Bittaye |e verfasserin |4 aut | |
700 | 0 | |a Timothy Tipoe |e verfasserin |4 aut | |
700 | 0 | |a Sandra Adele |e verfasserin |4 aut | |
700 | 0 | |a Jasmini Alagaratnam |e verfasserin |4 aut | |
700 | 0 | |a Parvinder K. Aley |e verfasserin |4 aut | |
700 | 0 | |a M. Azim Ansari |e verfasserin |4 aut | |
700 | 0 | |a Anna Bara |e verfasserin |4 aut | |
700 | 0 | |a Samantha Broadhead |e verfasserin |4 aut | |
700 | 0 | |a Anthony Brown |e verfasserin |4 aut | |
700 | 0 | |a Helen Brown |e verfasserin |4 aut | |
700 | 0 | |a Federica Cappuccini |e verfasserin |4 aut | |
700 | 0 | |a Paola Cinardo |e verfasserin |4 aut | |
700 | 0 | |a Wanwisa Dejnirattisai |e verfasserin |4 aut | |
700 | 0 | |a Katie J. Ewer |e verfasserin |4 aut | |
700 | 0 | |a Henry Fok |e verfasserin |4 aut | |
700 | 0 | |a Pedro M. Folegatti |e verfasserin |4 aut | |
700 | 0 | |a Jamie Fowler |e verfasserin |4 aut | |
700 | 0 | |a Leila Godfrey |e verfasserin |4 aut | |
700 | 0 | |a Anna L. Goodman |e verfasserin |4 aut | |
700 | 0 | |a Bethany Jackson |e verfasserin |4 aut | |
700 | 0 | |a Daniel Jenkin |e verfasserin |4 aut | |
700 | 0 | |a Mathew Jones |e verfasserin |4 aut | |
700 | 0 | |a Stephanie Longet |e verfasserin |4 aut | |
700 | 0 | |a Rebecca A. Makinson |e verfasserin |4 aut | |
700 | 0 | |a Natalie G. Marchevsky |e verfasserin |4 aut | |
700 | 0 | |a Moncy Mathew |e verfasserin |4 aut | |
700 | 0 | |a Andrea Mazzella |e verfasserin |4 aut | |
700 | 0 | |a Yama F. Mujadidi |e verfasserin |4 aut | |
700 | 0 | |a Lucia Parolini |e verfasserin |4 aut | |
700 | 0 | |a Claire Petersen |e verfasserin |4 aut | |
700 | 0 | |a Emma Plested |e verfasserin |4 aut | |
700 | 0 | |a Katrina M. Pollock |e verfasserin |4 aut | |
700 | 0 | |a Thurkka Rajeswaran |e verfasserin |4 aut | |
700 | 0 | |a Maheshi N. Ramasamy |e verfasserin |4 aut | |
700 | 0 | |a Sarah Rhead |e verfasserin |4 aut | |
700 | 0 | |a Hannah Robinson |e verfasserin |4 aut | |
700 | 0 | |a Nicola Robinson |e verfasserin |4 aut | |
700 | 0 | |a Helen Sanders |e verfasserin |4 aut | |
700 | 0 | |a Sonia Serrano |e verfasserin |4 aut | |
700 | 0 | |a Tom Tipton |e verfasserin |4 aut | |
700 | 0 | |a Anele Waters |e verfasserin |4 aut | |
700 | 0 | |a Panagiota Zacharopoulou |e verfasserin |4 aut | |
700 | 0 | |a Eleanor Barnes |e verfasserin |4 aut | |
700 | 0 | |a Susanna Dunachie |e verfasserin |4 aut | |
700 | 0 | |a Philip Goulder |e verfasserin |4 aut | |
700 | 0 | |a Paul Klenerman |e verfasserin |4 aut | |
700 | 0 | |a Gavin R. Screaton |e verfasserin |4 aut | |
700 | 0 | |a Alan Winston |e verfasserin |4 aut | |
700 | 0 | |a Adrian V.S. Hill |e verfasserin |4 aut | |
700 | 0 | |a Sarah C. Gilbert |e verfasserin |4 aut | |
700 | 0 | |a Miles Carroll |e verfasserin |4 aut | |
700 | 0 | |a Andrew J. Pollard |e verfasserin |4 aut | |
700 | 0 | |a Sarah Fidler |e verfasserin |4 aut | |
700 | 0 | |a Julie Fox |e verfasserin |4 aut | |
700 | 0 | |a Teresa Lambe |e verfasserin |4 aut | |
700 | 0 | |a John Frater |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t JCI Insight |d American Society for Clinical investigation, 2020 |g 7(2022), 7 |w (DE-627)872610594 |w (DE-600)2874757-4 |x 23793708 |7 nnns |
773 | 1 | 8 | |g volume:7 |g year:2022 |g number:7 |
856 | 4 | 0 | |u https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066 |z kostenfrei |
856 | 4 | 0 | |u https://doi.org/10.1172/jci.insight.157031 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2379-3708 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 7 |j 2022 |e 7 |
author_variant |
a o ao m p mp m b mb t t tt s a sa j a ja p k a pka m a a maa a b ab s b sb a b ab h b hb f c fc p c pc w d wd k j e kje h f hf p m f pmf j f jf l g lg a l g alg b j bj d j dj m j mj s l sl r a m ram n g m ngm m m mm a m am y f m yfm l p lp c p cp e p ep k m p kmp t r tr m n r mnr s r sr h r hr n r nr h s hs s s ss t t tt a w aw p z pz e b eb s d sd p g pg p k pk g r s grs a w aw a v h avh s c g scg m c mc a j p ajp s f sf j f jf t l tl j f jf |
---|---|
matchkey_str |
article:23793708:2022----::uaiiyfhdxno1vciainnep |
hierarchy_sort_str |
2022 |
publishDate |
2022 |
allfields |
(DE-627)DOAJ043577830 (DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066 DE-627 ger DE-627 rakwb eng Ane Ogbe verfasserin aut Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. AIDS/HIV COVID-19 Medicine R Matthew Pace verfasserin aut Mustapha Bittaye verfasserin aut Timothy Tipoe verfasserin aut Sandra Adele verfasserin aut Jasmini Alagaratnam verfasserin aut Parvinder K. Aley verfasserin aut M. Azim Ansari verfasserin aut Anna Bara verfasserin aut Samantha Broadhead verfasserin aut Anthony Brown verfasserin aut Helen Brown verfasserin aut Federica Cappuccini verfasserin aut Paola Cinardo verfasserin aut Wanwisa Dejnirattisai verfasserin aut Katie J. Ewer verfasserin aut Henry Fok verfasserin aut Pedro M. Folegatti verfasserin aut Jamie Fowler verfasserin aut Leila Godfrey verfasserin aut Anna L. Goodman verfasserin aut Bethany Jackson verfasserin aut Daniel Jenkin verfasserin aut Mathew Jones verfasserin aut Stephanie Longet verfasserin aut Rebecca A. Makinson verfasserin aut Natalie G. Marchevsky verfasserin aut Moncy Mathew verfasserin aut Andrea Mazzella verfasserin aut Yama F. Mujadidi verfasserin aut Lucia Parolini verfasserin aut Claire Petersen verfasserin aut Emma Plested verfasserin aut Katrina M. Pollock verfasserin aut Thurkka Rajeswaran verfasserin aut Maheshi N. Ramasamy verfasserin aut Sarah Rhead verfasserin aut Hannah Robinson verfasserin aut Nicola Robinson verfasserin aut Helen Sanders verfasserin aut Sonia Serrano verfasserin aut Tom Tipton verfasserin aut Anele Waters verfasserin aut Panagiota Zacharopoulou verfasserin aut Eleanor Barnes verfasserin aut Susanna Dunachie verfasserin aut Philip Goulder verfasserin aut Paul Klenerman verfasserin aut Gavin R. Screaton verfasserin aut Alan Winston verfasserin aut Adrian V.S. Hill verfasserin aut Sarah C. Gilbert verfasserin aut Miles Carroll verfasserin aut Andrew J. Pollard verfasserin aut Sarah Fidler verfasserin aut Julie Fox verfasserin aut Teresa Lambe verfasserin aut John Frater verfasserin aut In JCI Insight American Society for Clinical investigation, 2020 7(2022), 7 (DE-627)872610594 (DE-600)2874757-4 23793708 nnns volume:7 year:2022 number:7 https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066 kostenfrei https://doi.org/10.1172/jci.insight.157031 kostenfrei https://doaj.org/toc/2379-3708 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2022 7 |
spelling |
(DE-627)DOAJ043577830 (DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066 DE-627 ger DE-627 rakwb eng Ane Ogbe verfasserin aut Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. AIDS/HIV COVID-19 Medicine R Matthew Pace verfasserin aut Mustapha Bittaye verfasserin aut Timothy Tipoe verfasserin aut Sandra Adele verfasserin aut Jasmini Alagaratnam verfasserin aut Parvinder K. Aley verfasserin aut M. Azim Ansari verfasserin aut Anna Bara verfasserin aut Samantha Broadhead verfasserin aut Anthony Brown verfasserin aut Helen Brown verfasserin aut Federica Cappuccini verfasserin aut Paola Cinardo verfasserin aut Wanwisa Dejnirattisai verfasserin aut Katie J. Ewer verfasserin aut Henry Fok verfasserin aut Pedro M. Folegatti verfasserin aut Jamie Fowler verfasserin aut Leila Godfrey verfasserin aut Anna L. Goodman verfasserin aut Bethany Jackson verfasserin aut Daniel Jenkin verfasserin aut Mathew Jones verfasserin aut Stephanie Longet verfasserin aut Rebecca A. Makinson verfasserin aut Natalie G. Marchevsky verfasserin aut Moncy Mathew verfasserin aut Andrea Mazzella verfasserin aut Yama F. Mujadidi verfasserin aut Lucia Parolini verfasserin aut Claire Petersen verfasserin aut Emma Plested verfasserin aut Katrina M. Pollock verfasserin aut Thurkka Rajeswaran verfasserin aut Maheshi N. Ramasamy verfasserin aut Sarah Rhead verfasserin aut Hannah Robinson verfasserin aut Nicola Robinson verfasserin aut Helen Sanders verfasserin aut Sonia Serrano verfasserin aut Tom Tipton verfasserin aut Anele Waters verfasserin aut Panagiota Zacharopoulou verfasserin aut Eleanor Barnes verfasserin aut Susanna Dunachie verfasserin aut Philip Goulder verfasserin aut Paul Klenerman verfasserin aut Gavin R. Screaton verfasserin aut Alan Winston verfasserin aut Adrian V.S. Hill verfasserin aut Sarah C. Gilbert verfasserin aut Miles Carroll verfasserin aut Andrew J. Pollard verfasserin aut Sarah Fidler verfasserin aut Julie Fox verfasserin aut Teresa Lambe verfasserin aut John Frater verfasserin aut In JCI Insight American Society for Clinical investigation, 2020 7(2022), 7 (DE-627)872610594 (DE-600)2874757-4 23793708 nnns volume:7 year:2022 number:7 https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066 kostenfrei https://doi.org/10.1172/jci.insight.157031 kostenfrei https://doaj.org/toc/2379-3708 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2022 7 |
allfields_unstemmed |
(DE-627)DOAJ043577830 (DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066 DE-627 ger DE-627 rakwb eng Ane Ogbe verfasserin aut Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. AIDS/HIV COVID-19 Medicine R Matthew Pace verfasserin aut Mustapha Bittaye verfasserin aut Timothy Tipoe verfasserin aut Sandra Adele verfasserin aut Jasmini Alagaratnam verfasserin aut Parvinder K. Aley verfasserin aut M. Azim Ansari verfasserin aut Anna Bara verfasserin aut Samantha Broadhead verfasserin aut Anthony Brown verfasserin aut Helen Brown verfasserin aut Federica Cappuccini verfasserin aut Paola Cinardo verfasserin aut Wanwisa Dejnirattisai verfasserin aut Katie J. Ewer verfasserin aut Henry Fok verfasserin aut Pedro M. Folegatti verfasserin aut Jamie Fowler verfasserin aut Leila Godfrey verfasserin aut Anna L. Goodman verfasserin aut Bethany Jackson verfasserin aut Daniel Jenkin verfasserin aut Mathew Jones verfasserin aut Stephanie Longet verfasserin aut Rebecca A. Makinson verfasserin aut Natalie G. Marchevsky verfasserin aut Moncy Mathew verfasserin aut Andrea Mazzella verfasserin aut Yama F. Mujadidi verfasserin aut Lucia Parolini verfasserin aut Claire Petersen verfasserin aut Emma Plested verfasserin aut Katrina M. Pollock verfasserin aut Thurkka Rajeswaran verfasserin aut Maheshi N. Ramasamy verfasserin aut Sarah Rhead verfasserin aut Hannah Robinson verfasserin aut Nicola Robinson verfasserin aut Helen Sanders verfasserin aut Sonia Serrano verfasserin aut Tom Tipton verfasserin aut Anele Waters verfasserin aut Panagiota Zacharopoulou verfasserin aut Eleanor Barnes verfasserin aut Susanna Dunachie verfasserin aut Philip Goulder verfasserin aut Paul Klenerman verfasserin aut Gavin R. Screaton verfasserin aut Alan Winston verfasserin aut Adrian V.S. Hill verfasserin aut Sarah C. Gilbert verfasserin aut Miles Carroll verfasserin aut Andrew J. Pollard verfasserin aut Sarah Fidler verfasserin aut Julie Fox verfasserin aut Teresa Lambe verfasserin aut John Frater verfasserin aut In JCI Insight American Society for Clinical investigation, 2020 7(2022), 7 (DE-627)872610594 (DE-600)2874757-4 23793708 nnns volume:7 year:2022 number:7 https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066 kostenfrei https://doi.org/10.1172/jci.insight.157031 kostenfrei https://doaj.org/toc/2379-3708 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2022 7 |
allfieldsGer |
(DE-627)DOAJ043577830 (DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066 DE-627 ger DE-627 rakwb eng Ane Ogbe verfasserin aut Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. AIDS/HIV COVID-19 Medicine R Matthew Pace verfasserin aut Mustapha Bittaye verfasserin aut Timothy Tipoe verfasserin aut Sandra Adele verfasserin aut Jasmini Alagaratnam verfasserin aut Parvinder K. Aley verfasserin aut M. Azim Ansari verfasserin aut Anna Bara verfasserin aut Samantha Broadhead verfasserin aut Anthony Brown verfasserin aut Helen Brown verfasserin aut Federica Cappuccini verfasserin aut Paola Cinardo verfasserin aut Wanwisa Dejnirattisai verfasserin aut Katie J. Ewer verfasserin aut Henry Fok verfasserin aut Pedro M. Folegatti verfasserin aut Jamie Fowler verfasserin aut Leila Godfrey verfasserin aut Anna L. Goodman verfasserin aut Bethany Jackson verfasserin aut Daniel Jenkin verfasserin aut Mathew Jones verfasserin aut Stephanie Longet verfasserin aut Rebecca A. Makinson verfasserin aut Natalie G. Marchevsky verfasserin aut Moncy Mathew verfasserin aut Andrea Mazzella verfasserin aut Yama F. Mujadidi verfasserin aut Lucia Parolini verfasserin aut Claire Petersen verfasserin aut Emma Plested verfasserin aut Katrina M. Pollock verfasserin aut Thurkka Rajeswaran verfasserin aut Maheshi N. Ramasamy verfasserin aut Sarah Rhead verfasserin aut Hannah Robinson verfasserin aut Nicola Robinson verfasserin aut Helen Sanders verfasserin aut Sonia Serrano verfasserin aut Tom Tipton verfasserin aut Anele Waters verfasserin aut Panagiota Zacharopoulou verfasserin aut Eleanor Barnes verfasserin aut Susanna Dunachie verfasserin aut Philip Goulder verfasserin aut Paul Klenerman verfasserin aut Gavin R. Screaton verfasserin aut Alan Winston verfasserin aut Adrian V.S. Hill verfasserin aut Sarah C. Gilbert verfasserin aut Miles Carroll verfasserin aut Andrew J. Pollard verfasserin aut Sarah Fidler verfasserin aut Julie Fox verfasserin aut Teresa Lambe verfasserin aut John Frater verfasserin aut In JCI Insight American Society for Clinical investigation, 2020 7(2022), 7 (DE-627)872610594 (DE-600)2874757-4 23793708 nnns volume:7 year:2022 number:7 https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066 kostenfrei https://doi.org/10.1172/jci.insight.157031 kostenfrei https://doaj.org/toc/2379-3708 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2022 7 |
allfieldsSound |
(DE-627)DOAJ043577830 (DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066 DE-627 ger DE-627 rakwb eng Ane Ogbe verfasserin aut Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. AIDS/HIV COVID-19 Medicine R Matthew Pace verfasserin aut Mustapha Bittaye verfasserin aut Timothy Tipoe verfasserin aut Sandra Adele verfasserin aut Jasmini Alagaratnam verfasserin aut Parvinder K. Aley verfasserin aut M. Azim Ansari verfasserin aut Anna Bara verfasserin aut Samantha Broadhead verfasserin aut Anthony Brown verfasserin aut Helen Brown verfasserin aut Federica Cappuccini verfasserin aut Paola Cinardo verfasserin aut Wanwisa Dejnirattisai verfasserin aut Katie J. Ewer verfasserin aut Henry Fok verfasserin aut Pedro M. Folegatti verfasserin aut Jamie Fowler verfasserin aut Leila Godfrey verfasserin aut Anna L. Goodman verfasserin aut Bethany Jackson verfasserin aut Daniel Jenkin verfasserin aut Mathew Jones verfasserin aut Stephanie Longet verfasserin aut Rebecca A. Makinson verfasserin aut Natalie G. Marchevsky verfasserin aut Moncy Mathew verfasserin aut Andrea Mazzella verfasserin aut Yama F. Mujadidi verfasserin aut Lucia Parolini verfasserin aut Claire Petersen verfasserin aut Emma Plested verfasserin aut Katrina M. Pollock verfasserin aut Thurkka Rajeswaran verfasserin aut Maheshi N. Ramasamy verfasserin aut Sarah Rhead verfasserin aut Hannah Robinson verfasserin aut Nicola Robinson verfasserin aut Helen Sanders verfasserin aut Sonia Serrano verfasserin aut Tom Tipton verfasserin aut Anele Waters verfasserin aut Panagiota Zacharopoulou verfasserin aut Eleanor Barnes verfasserin aut Susanna Dunachie verfasserin aut Philip Goulder verfasserin aut Paul Klenerman verfasserin aut Gavin R. Screaton verfasserin aut Alan Winston verfasserin aut Adrian V.S. Hill verfasserin aut Sarah C. Gilbert verfasserin aut Miles Carroll verfasserin aut Andrew J. Pollard verfasserin aut Sarah Fidler verfasserin aut Julie Fox verfasserin aut Teresa Lambe verfasserin aut John Frater verfasserin aut In JCI Insight American Society for Clinical investigation, 2020 7(2022), 7 (DE-627)872610594 (DE-600)2874757-4 23793708 nnns volume:7 year:2022 number:7 https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066 kostenfrei https://doi.org/10.1172/jci.insight.157031 kostenfrei https://doaj.org/toc/2379-3708 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2022 7 |
language |
English |
source |
In JCI Insight 7(2022), 7 volume:7 year:2022 number:7 |
sourceStr |
In JCI Insight 7(2022), 7 volume:7 year:2022 number:7 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
AIDS/HIV COVID-19 Medicine R |
isfreeaccess_bool |
true |
container_title |
JCI Insight |
authorswithroles_txt_mv |
Ane Ogbe @@aut@@ Matthew Pace @@aut@@ Mustapha Bittaye @@aut@@ Timothy Tipoe @@aut@@ Sandra Adele @@aut@@ Jasmini Alagaratnam @@aut@@ Parvinder K. Aley @@aut@@ M. Azim Ansari @@aut@@ Anna Bara @@aut@@ Samantha Broadhead @@aut@@ Anthony Brown @@aut@@ Helen Brown @@aut@@ Federica Cappuccini @@aut@@ Paola Cinardo @@aut@@ Wanwisa Dejnirattisai @@aut@@ Katie J. Ewer @@aut@@ Henry Fok @@aut@@ Pedro M. Folegatti @@aut@@ Jamie Fowler @@aut@@ Leila Godfrey @@aut@@ Anna L. Goodman @@aut@@ Bethany Jackson @@aut@@ Daniel Jenkin @@aut@@ Mathew Jones @@aut@@ Stephanie Longet @@aut@@ Rebecca A. Makinson @@aut@@ Natalie G. Marchevsky @@aut@@ Moncy Mathew @@aut@@ Andrea Mazzella @@aut@@ Yama F. Mujadidi @@aut@@ Lucia Parolini @@aut@@ Claire Petersen @@aut@@ Emma Plested @@aut@@ Katrina M. Pollock @@aut@@ Thurkka Rajeswaran @@aut@@ Maheshi N. Ramasamy @@aut@@ Sarah Rhead @@aut@@ Hannah Robinson @@aut@@ Nicola Robinson @@aut@@ Helen Sanders @@aut@@ Sonia Serrano @@aut@@ Tom Tipton @@aut@@ Anele Waters @@aut@@ Panagiota Zacharopoulou @@aut@@ Eleanor Barnes @@aut@@ Susanna Dunachie @@aut@@ Philip Goulder @@aut@@ Paul Klenerman @@aut@@ Gavin R. Screaton @@aut@@ Alan Winston @@aut@@ Adrian V.S. Hill @@aut@@ Sarah C. Gilbert @@aut@@ Miles Carroll @@aut@@ Andrew J. Pollard @@aut@@ Sarah Fidler @@aut@@ Julie Fox @@aut@@ Teresa Lambe @@aut@@ John Frater @@aut@@ |
publishDateDaySort_date |
2022-01-01T00:00:00Z |
hierarchy_top_id |
872610594 |
id |
DOAJ043577830 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ043577830</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308072853.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ043577830</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ane Ogbe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells &gt; 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">AIDS/HIV</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">COVID-19</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Matthew Pace</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mustapha Bittaye</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Timothy Tipoe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sandra Adele</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jasmini Alagaratnam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Parvinder K. Aley</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. Azim Ansari</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Bara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Samantha Broadhead</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anthony Brown</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Helen Brown</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Federica Cappuccini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paola Cinardo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wanwisa Dejnirattisai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katie J. Ewer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Henry Fok</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pedro M. Folegatti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jamie Fowler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Leila Godfrey</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna L. Goodman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bethany Jackson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daniel Jenkin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mathew Jones</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stephanie Longet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rebecca A. Makinson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Natalie G. Marchevsky</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Moncy Mathew</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrea Mazzella</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yama F. Mujadidi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lucia Parolini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Claire Petersen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Emma Plested</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katrina M. Pollock</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thurkka Rajeswaran</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maheshi N. Ramasamy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sarah Rhead</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hannah Robinson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicola Robinson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Helen Sanders</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sonia Serrano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tom Tipton</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anele Waters</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Panagiota Zacharopoulou</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eleanor Barnes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Susanna Dunachie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Philip Goulder</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paul Klenerman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gavin R. Screaton</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alan Winston</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Adrian V.S. Hill</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sarah C. Gilbert</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Miles Carroll</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrew J. Pollard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sarah Fidler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Julie Fox</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Teresa Lambe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">John Frater</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">JCI Insight</subfield><subfield code="d">American Society for Clinical investigation, 2020</subfield><subfield code="g">7(2022), 7</subfield><subfield code="w">(DE-627)872610594</subfield><subfield code="w">(DE-600)2874757-4</subfield><subfield code="x">23793708</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1172/jci.insight.157031</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2379-3708</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2022</subfield><subfield code="e">7</subfield></datafield></record></collection>
|
author |
Ane Ogbe |
spellingShingle |
Ane Ogbe misc AIDS/HIV misc COVID-19 misc Medicine misc R Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
authorStr |
Ane Ogbe |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)872610594 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
23793708 |
topic_title |
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV AIDS/HIV COVID-19 |
topic |
misc AIDS/HIV misc COVID-19 misc Medicine misc R |
topic_unstemmed |
misc AIDS/HIV misc COVID-19 misc Medicine misc R |
topic_browse |
misc AIDS/HIV misc COVID-19 misc Medicine misc R |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
JCI Insight |
hierarchy_parent_id |
872610594 |
hierarchy_top_title |
JCI Insight |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)872610594 (DE-600)2874757-4 |
title |
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
ctrlnum |
(DE-627)DOAJ043577830 (DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066 |
title_full |
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
author_sort |
Ane Ogbe |
journal |
JCI Insight |
journalStr |
JCI Insight |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2022 |
contenttype_str_mv |
txt |
author_browse |
Ane Ogbe Matthew Pace Mustapha Bittaye Timothy Tipoe Sandra Adele Jasmini Alagaratnam Parvinder K. Aley M. Azim Ansari Anna Bara Samantha Broadhead Anthony Brown Helen Brown Federica Cappuccini Paola Cinardo Wanwisa Dejnirattisai Katie J. Ewer Henry Fok Pedro M. Folegatti Jamie Fowler Leila Godfrey Anna L. Goodman Bethany Jackson Daniel Jenkin Mathew Jones Stephanie Longet Rebecca A. Makinson Natalie G. Marchevsky Moncy Mathew Andrea Mazzella Yama F. Mujadidi Lucia Parolini Claire Petersen Emma Plested Katrina M. Pollock Thurkka Rajeswaran Maheshi N. Ramasamy Sarah Rhead Hannah Robinson Nicola Robinson Helen Sanders Sonia Serrano Tom Tipton Anele Waters Panagiota Zacharopoulou Eleanor Barnes Susanna Dunachie Philip Goulder Paul Klenerman Gavin R. Screaton Alan Winston Adrian V.S. Hill Sarah C. Gilbert Miles Carroll Andrew J. Pollard Sarah Fidler Julie Fox Teresa Lambe John Frater |
container_volume |
7 |
format_se |
Elektronische Aufsätze |
author-letter |
Ane Ogbe |
author2-role |
verfasserin |
title_sort |
durability of chadox1 ncov-19 vaccination in people living with hiv |
title_auth |
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
abstract |
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. |
abstractGer |
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. |
abstract_unstemmed |
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
7 |
title_short |
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
url |
https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066 https://doi.org/10.1172/jci.insight.157031 https://doaj.org/toc/2379-3708 |
remote_bool |
true |
author2 |
Matthew Pace Mustapha Bittaye Timothy Tipoe Sandra Adele Jasmini Alagaratnam Parvinder K. Aley M. Azim Ansari Anna Bara Samantha Broadhead Anthony Brown Helen Brown Federica Cappuccini Paola Cinardo Wanwisa Dejnirattisai Katie J. Ewer Henry Fok Pedro M. Folegatti Jamie Fowler Leila Godfrey Anna L. Goodman Bethany Jackson Daniel Jenkin Mathew Jones Stephanie Longet Rebecca A. Makinson Natalie G. Marchevsky Moncy Mathew Andrea Mazzella Yama F. Mujadidi Lucia Parolini Claire Petersen Emma Plested Katrina M. Pollock Thurkka Rajeswaran Maheshi N. Ramasamy Sarah Rhead Hannah Robinson Nicola Robinson Helen Sanders Sonia Serrano Tom Tipton Anele Waters Panagiota Zacharopoulou Eleanor Barnes Susanna Dunachie Philip Goulder Paul Klenerman Gavin R. Screaton Alan Winston Adrian V.S. Hill Sarah C. Gilbert Miles Carroll Andrew J. Pollard Sarah Fidler Julie Fox Teresa Lambe John Frater |
author2Str |
Matthew Pace Mustapha Bittaye Timothy Tipoe Sandra Adele Jasmini Alagaratnam Parvinder K. Aley M. Azim Ansari Anna Bara Samantha Broadhead Anthony Brown Helen Brown Federica Cappuccini Paola Cinardo Wanwisa Dejnirattisai Katie J. Ewer Henry Fok Pedro M. Folegatti Jamie Fowler Leila Godfrey Anna L. Goodman Bethany Jackson Daniel Jenkin Mathew Jones Stephanie Longet Rebecca A. Makinson Natalie G. Marchevsky Moncy Mathew Andrea Mazzella Yama F. Mujadidi Lucia Parolini Claire Petersen Emma Plested Katrina M. Pollock Thurkka Rajeswaran Maheshi N. Ramasamy Sarah Rhead Hannah Robinson Nicola Robinson Helen Sanders Sonia Serrano Tom Tipton Anele Waters Panagiota Zacharopoulou Eleanor Barnes Susanna Dunachie Philip Goulder Paul Klenerman Gavin R. Screaton Alan Winston Adrian V.S. Hill Sarah C. Gilbert Miles Carroll Andrew J. Pollard Sarah Fidler Julie Fox Teresa Lambe John Frater |
ppnlink |
872610594 |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
up_date |
2024-07-03T18:19:10.194Z |
_version_ |
1803582963916472320 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ043577830</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308072853.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ043577830</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ane Ogbe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells &gt; 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">AIDS/HIV</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">COVID-19</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Matthew Pace</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mustapha Bittaye</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Timothy Tipoe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sandra Adele</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jasmini Alagaratnam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Parvinder K. Aley</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. Azim Ansari</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Bara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Samantha Broadhead</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anthony Brown</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Helen Brown</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Federica Cappuccini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paola Cinardo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wanwisa Dejnirattisai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katie J. Ewer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Henry Fok</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pedro M. Folegatti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jamie Fowler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Leila Godfrey</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna L. Goodman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bethany Jackson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daniel Jenkin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mathew Jones</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stephanie Longet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rebecca A. Makinson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Natalie G. Marchevsky</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Moncy Mathew</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrea Mazzella</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yama F. Mujadidi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lucia Parolini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Claire Petersen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Emma Plested</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katrina M. Pollock</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thurkka Rajeswaran</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maheshi N. Ramasamy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sarah Rhead</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hannah Robinson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicola Robinson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Helen Sanders</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sonia Serrano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tom Tipton</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anele Waters</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Panagiota Zacharopoulou</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eleanor Barnes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Susanna Dunachie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Philip Goulder</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paul Klenerman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gavin R. Screaton</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alan Winston</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Adrian V.S. Hill</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sarah C. Gilbert</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Miles Carroll</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrew J. Pollard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sarah Fidler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Julie Fox</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Teresa Lambe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">John Frater</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">JCI Insight</subfield><subfield code="d">American Society for Clinical investigation, 2020</subfield><subfield code="g">7(2022), 7</subfield><subfield code="w">(DE-627)872610594</subfield><subfield code="w">(DE-600)2874757-4</subfield><subfield code="x">23793708</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1172/jci.insight.157031</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2379-3708</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2022</subfield><subfield code="e">7</subfield></datafield></record></collection>
|
score |
7.4020653 |